ARTICLE | Clinical News
Exforge HCT regulatory update
August 3, 2009 7:00 AM UTC
EMEA's CHMP issued a positive opinion on an MAA from Novartis for Exforge HCT amlodipine/valsartan/hydrochlorothiazide to treat essential hypertension as substitution therapy in adults whose blood pre...